Yuheng Pharmaceutical announced that the company signed a joint promotion agreement with Xinghe Pharmaceutical Co., Ltd. on Pemabet tablets on May 23, 2025. The agreement will take effect on June 1, 2025, with an initial term until December 31, 2027, and will be automatically renewed thereafter. According to the agreement, Xinghe Pharmaceutical authorizes Yuheng Pharmaceutical to promote Pemabet tablets in designated areas and pay service fees and promotion support fees. Pemabet tablets are the world's first new highly selective PPARα modulator, mainly used to reduce triglyceride levels in adult patients with non-familial hypertriglyceridemia. This cooperation will enrich Yuheng Pharmaceutical's product line and enhance its competitiveness in the cardiovascular and cerebrovascular fields.